Retinoblastoma is a rare type of cancer that affects the retina, the tissue at the back of the eye responsible for detecting light and sending visual signals to the brain. This cancer typically occurs in children under five years of age and can be caused by mutations in the RB1 gene.
The RB1 gene provides instructions for making a protein called pRB, which helps regulate cell division and prevent uncontrolled growth. Mutations in this gene can disrupt normal cell cycle regulation, leading to abnormal growth and tumor formation.
There are two types of retinoblastoma: hereditary and non-hereditary. Hereditary retinoblastoma is caused by an inherited mutation in one copy of the RB1 gene, while non-hereditary (sporadic) retinoblastoma occurs when both copies of the RB1 gene become mutated during early development.
Individuals with hereditary retinoblastoma have a higher risk of developing tumors in both eyes or multiple tumors within one eye compared to those with sporadic cases. In addition, individuals with hereditary retinoblastoma have an increased risk of developing other types of cancers later in life, including osteosarcoma (bone cancer) and soft tissue sarcomas.
Genetic testing can help identify individuals who carry mutations in their RB1 genes before they develop symptoms or signs of retinoblastoma. If a mutation is found, regular eye exams can be performed to detect tumors early on when they are more easily treated.
Treatment options for retinoblastoma depend on several factors such as tumor size, location, number, and whether it has spread beyond the eye. Common treatment methods include chemotherapy, radiation therapy, laser therapy or cryotherapy (freezing), or surgery to remove affected tissues if necessary.
In conclusion, understanding how mutations in the RB1 gene contribute to retinoblastoma is crucial for identifying individuals at risk of developing this cancer and providing them with appropriate screening and treatment options. Early detection and intervention can greatly improve the chances of survival for those affected by retinoblastoma.